Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGOR: vorasidenib maintenance after first-line chemoradiotherapy in IDH-mutant astrocytoma
2024-519404-27-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, triple-blind trial in astrocytoma comparing Vorasidenib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2026; status: authorised.
02
Drugs
vorasidenib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on 2024-519404-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519404-27-00.